BiotechTube
Abscint

Abscint

Leuven, Belgium· Est.
abscint.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Abscint is pioneering a novel diagnostic approach in oncology through its platform for developing sdAb-based PET imaging tracers. The company's lead candidate, a 68Ga-labeled anti-HER2 tracer, is designed to illuminate HER2-positive metastases throughout the body, addressing critical unmet needs in patient selection, treatment monitoring, and biopsy guidance. Founded in 2019 and based in Leuven's biotech hub, Abscint is positioning its technology as a faster, safer, and more precise alternative to invasive biopsies and conventional imaging, with the potential to transform personalized cancer care.

Oncology

Technology Platform

Platform for developing single-domain antibody (sdAb) based PET imaging tracers. Utilizes small, fast-clearing sdAbs labeled with short-half-life radioisotopes (e.g., Gallium-68) to create 'cold kits' for decentralized production of diagnostic agents.

Opportunities

The growing demand for non-invasive, whole-body companion diagnostics in precision oncology represents a major opportunity.
Success with the HER2 tracer could validate the platform for rapid expansion into other high-value targets in oncology, immunology, and cardiology.
The 'cold kit' production model offers a scalable and commercially attractive pathway for global distribution.

Risk Factors

Key risks include the clinical and regulatory risk of demonstrating superior utility over standard biopsies, the challenge of achieving market adoption and reimbursement, and competition from other imaging agents and diagnostic technologies.
As a pre-revenue startup, the company is also dependent on securing ongoing funding.

Competitive Landscape

Abscint competes in the targeted radiopharmaceutical diagnostics space. Competitors include large radiopharma companies (e.g., GE HealthCare, Lantheus) and biotechs developing antibody-based PET tracers. Its primary differentiation is the use of sdAbs for rapid imaging and a platform focused on cold kit production, aiming for faster, more convenient patient scans compared to traditional antibody fragments.

More companies in Radiopharmaceuticals →More companies in Belgium →